Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT02623998

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02623998
Other papers using this trial's data
  • Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial Diabetes care, 2022-01-01 DOI, PubMed 34728531

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02623998. Randomized; no masking; primary purpose treatment. Start 2016-07-09 (actual); primary completion 2018-09-01 (actual). Results posted on 2022-03-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
insulin glargine
Intervention (Drug)
sitagliptin/metformin
Intervention (Behavioral)
lifestyle therapy
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02623998
Content hash
8dee205e76453989f2125e991aa1cdd35a4c937e3d6985aedb21d0fc0490c271